Alphatide, Explained: The AI-Found Peptide Behind a New Non-Hormonal Male Contraceptive

Published October 28, 2026 · Investigational · Not approved

On October 22, 2026 the Washington Research Foundation (WRF) announced a $274,849 grant to Jon Oatley, Ph.D., of Washington State University (WSU), to advance Alphatide, a short peptide his lab is developing as a non-hormonal, reversible male contraceptive. Alphatide is preclinical: it has only been tested in mice, it has never been given to people, and it is not approved anywhere.

The target: two proteins found only in sperm-making cells

The story starts with a gene called Arrdc5. In 2023, WSU reported that Oatley's team found the gene is expressed only in testicular tissue, in mice, pigs, cattle and humans. Male mice bred without it produced 28% less sperm that moved 2.8 times slower, and about 98% of their sperm were misshapen. Oatley's reasoning: "You don't want to wipe out the ability to ever make sperm — just stop the sperm that are being made from being made correctly."

The lab later showed that ARRDC5 works with a partner protein, TEX38. In a Cell Reports paper, the team reported that the two testis-specific proteins physically interact and are needed for sperm to mature normally. According to WRF, blocking that interaction is meant to stop sperm from maturing without affecting testosterone or other hormones.

How AI helped find it

With a $100,000 WRF grant in 2023, Oatley and postdoctoral researcher Mingyao Yang, Ph.D., studied the ARRDC5–TEX38 interaction. They then used AI-driven screening of FDA-approved drugs to find an existing peptide that blocks it, WRF says. The team then modeled more than 2,000 variations of that peptide. The result, Alphatide, is predicted to bind its target more tightly and stay stable in the body longer. Those are computer predictions that the new grant is meant to test.

What the mouse results showed

WRF reports that in male mice treated over 40 days, the original peptide (not yet Alphatide itself) reduced fertility by 85%, with no change in overall body weight or in the weight of organs associated with testosterone production. Fertility returned to normal within 21 days after treatment ended. These are early animal results described in a funder's announcement. Mouse findings often don't carry over to people, and an 85% reduction is not the same as reliably preventing pregnancy.

What the $274,849 pays for

Over 18 months, the grant funds preclinical studies to see whether Alphatide performs as designed. The team will measure its potency in cells, track how it moves through the body, and test whether continuous dosing in mice fully prevents pregnancy. Other studies aim to confirm that fertility comes back after treatment stops and that offspring conceived afterward develop normally. WSU has filed a provisional patent application, and Oatley expects the results to position Alphatide for licensing or a startup.

Why it's years from human trials

Before any human study, a drug needs IND-enabling studies, the safety and manufacturing work regulators require first. WRF says the new grant is meant to prepare the team for those studies, so they haven't started. After that would come Phase 1, Phase 2 and Phase 3 trials. For comparison, the non-hormonal pill YCT-529 completed its first, single-dose human study in 2024 and is still in early trials (see our YCT-529 update). Alphatide is investigational and not approved. For every candidate's stage, see the status tracker.

Get the next update

We follow these programs from registries, journals and developers, and we'll email when something real changes: trial results, new studies, regulatory filings. It's free and it's not a preorder. Join the update list.

This article is news and education, not medical advice. No male contraceptive described here is approved. Get notified of updates.